CARB-X Funding Round 4 - Direct-Acting Small Molecules
Nov 12 - 19
CARB-X’s 2019 Funding Round 4 will open for applications November 12 through November 19, 2019, 5 pm ET. Product developers with direct-acting small molecule projects are invited to apply on-line for funding and support.
The scope of Round 4 is highly specific, limited to new classes and/or new targets in early development phases (hit-to-lead through Phase 1) targeting a specific list of Gram-negative pathogens. Click here for full details.
This year, CARB-X has increased its cost share of product development to 80-90% of the project, depending on the phase of development. Product developers’ cost-share requirement is 10% for the Hit-to-Lead, Lead Optimization and Pre-clinical (IND-Enabling) stages, and 20% for the Phase 1 stage
Since it was established in 2016, CARB-X received more than 1000 applications for funding from product developers around the world. We have awarded $139.5 million in non-dilutive funding to support the development of 48 innovative antibiotics, vaccines, diagnostics and other products. Six companies have graduated from the CARB-X portfolio, successfully advancing their projects through development stages, while 13 projects have been stopped for various reasons.
The current portfolio supports 29 projects in five countries.
Full details of how to apply can be found here.